<DOC>
	<DOCNO>NCT00384449</DOCNO>
	<brief_summary>The primary objective protocol look whether Lucentis ( ranibizumab ) safe effective use macular edema ( retinal swelling ) due Eales ' disease . The secondary objective see macular edema come back within three month last dose study drug give .</brief_summary>
	<brief_title>Lucentis ( Ranibizumab ) Eales ' Disease</brief_title>
	<detailed_description>This six-month study . Eligible subject receive one injection study drug one eye three month . Visual acuity , blood pressure eye pressure test . Subjects ' retina examine thickness measure optical coherence tomography ( OCT ) . Safety visit schedule week injection . The investigator monitor subject ' eye infection inflammation . After three-month treatment period , subject return clinic monthly four follow-up visit . Procedures test perform follow-up visit include visual acuity , retinal exam include OCT , blood pressure , eye pressure .</detailed_description>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Retinal Vasculitis</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Ability provide write informed consent comply study assessment full duration study . Age &gt; 21 year . Disease related consideration : For treatment na√Øve previously treat patient : exclusion cause cystoid macular edema retinal nonperfusion include branch central vein occlusion , diabetic retinopathy , sickle retinopathy , sarcoidosis , systemic lupus collagen vascular disease chronic cystoid macular edema note clinically OCT 3 test persistent loss visual acuity 3 month long eye receive prior treatment ( include laser photocoagulation steroid ) 30 day washout period require prior treatment Lucentis . BCVA use ETDRS chart 20/40 20/400 ( Snellen equivalent ) study eye . OCT 3 central subfield &gt; = 250 2 separate reading central subfield . Only one eye assess study . If eye eligible , investigator determine eye enter study . Treatment macular edema intravitreal steroid macugen within 30 day prior enrollment study . Previous vitrectomy within past 6 month . Previous cataract surgery within precede 12 month . Active intraocular inflammation study eye . Current vitreous hemorrhage study eye . Active infectious conjunctivitis , keratitis , scleritis , endophthalmitis either eye . A condition , opinion investigator , would preclude participation study ( e.g. , unstable medical status include blood pressure , cardiovascular disease , glycemic control ) . Participation investigational trial within 30 day randomization involve . Treatment drug receive regulatory approval time study entry . Known allergy component study drug . Blood pressure &gt; 180/110 ( systolic 180 OR diastolic 110 ) . If blood pressure bring 180/110 antihypertensive treatment , subject become eligible . Major surgery within 28 day prior randomization major surgery plan next 6 month . Major surgery define surgical procedure extensive fine needle biopsy/aspiration , placement central venous access device , removal/biopsy skin lesion , placement peripheral venous catheter . Myocardial infarction , cardiac event require hospitalization , stroke , transient ischemic attack , treatment acute congestive heart failure within 6 month prior randomization . Systemic antiVEGF proVEGF treatment within 3 month prior randomization . Systemic antiVEGF proVEGF treatment use 6 month study . Current treatment active systemic infection . History recurrent significant infection bacterial infection . Subject expect move area clinical center area cover another clinical center 6 month study . Subjects meet follow criterion exclude study : Pregnancy ( positive pregnancy test ) . Prior enrollment study . Any condition investigator believe would pose significant hazard subject investigational therapy initiate . Participation another simultaneous medical investigation trial .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Eales</keyword>
</DOC>